This is an important step towards the EU disbursing €7 billion in grants under the Recovery and Resilience Facility. This financing will support the implementation of the crucial investment and reform measures outlined in Czechia’s recovery and resilience plan. The Commission disbursed €4 billion to Greece in pre-financing, equivalent to 13% of the country’s grant and loan allocation under the Recovery and Resilience Facility. The pre-financing will help to kick-start the implementation of the crucial investment and reform measures outlined in Greece’s recovery and resilience plan. The Commission disbursed €24.9 billion to Italy in pre-financing, equivalent to 13% of the country’s grant and loan allocation under the Recovery and Resilience Facility. The pre-financing will help to kick-start the implementation of the crucial investment and reform measures outlined in Italy’s recovery and resilience plan.

The Commission will use a diversified funding strategy to raise up to around €800 billion in current prices until 2026. This approach will enable the Commission to raise the needed volumes in a smooth and efficient way. It will also attract investors to Europe and strengthen the international role of the euro.

The pre-financing payment will help to kick-start the implementation of the crucial investment and reform measures outlined in Austria’s recovery and resilience plan. The Commission disbursed €818 million to Croatia in a pre-financing payment under the Recovery and Resilience Facility, which is equivalent to 13% of the country’s total financial allocation under the RRF. The pre-financing payment will help to kick-start the implementation of the crucial investment and reform measures outlined in Croatia’s recovery and resilience plan. The Commission adopted a positive assessment of Bulgaria’s recovery and resilience plan. This is a key step paving the way for the EU to disburse €6.3 billion in grants under the Recovery and Resilience Facility. This financing will support the implementation of the crucial investment and reform measures outlined in Bulgaria’s recovery and resilience plan.

What should I know before trading Pfizer stock?

The financing provided by the Recovery and Resilience Facility will support the implementation of the crucial investment and reform measures outlined in Estonia’s recovery and resilience plan. The Commission approved the eighth contract with a pharmaceutical company with a view to purchasing its potential vaccine against COVID-19. The contract with Valneva provides for the possibility for all EU Member States to purchase almost 27 million doses in 2022. It also includes the possibility to adapt the vaccine to new variant strains, and for Member States to make a further order of up to 33 million additional vaccines in 2023.

It will play a crucial role in enabling Bulgaria to emerge stronger from the COVID-19 pandemic. The Commission gave a positive assessment of Poland’s recovery and resilience plan, an important step towards the EU disbursing €23.9 billion in grants and €11.5 billion in loans under the Recovery and Resilience Facility. This financing will support the implementation of the crucial investment and reform measures outlined in Poland’s recovery and resilience plan.

The airline company reported an adjusted loss of 38 cents a share on revenues of $6.17 billion. Southwest said the winter storm meltdown contributed to an $800 million pre-tax hit to earnings. UBS downgraded shares of Pfizer to neutral from a buy rating as Covid-19 stabilizes and the company’s pipeline slows. The U.S. economy expanded at an annualized pace of 2.9% in the fourth quarter, slightly outperforming a Dow Jones estimate of 2.8%.

Moderna Says Its RSV Vaccine Trial Was a Success. A Clash With Pfizer and GSK Looms.

The envisaged contract would provide for the possibility for all EU Member States to purchase the vaccine. The Commission adopted a positive assessment of Germany’s recovery and resilience plan. This is an important step towards the EU disbursing €25.6 billion in grants under the Recovery and Resilience Facility. This financing will support the implementation of the crucial investment and reform measures outlined in Germany’s recovery and resilience plan. The Commission adopted a positive assessment of Belgium’s recovery and resilience plan, which is an important step towards the EU disbursing €5.9 billion in grants under the Recovery and Resilience Facility. This financing will support the implementation of the crucial investment and reform measures outlined in Belgium’s recovery and resilience plan.

• “We have delivered enough vaccines to Member States to be in a position to vaccinate fully at least 70% of EU adults still this month”, said Commission President Ursula von der Leyen as the EU marked a new milestone in the vaccination campaign on 11 July.
• The Commission disbursed €450 million to Austria in a pre-financing payment under the Recovery and Resilience Facility.
• The Commission disbursed €271 million to Finland in pre-financing, equivalent to 13% of the country’s financial allocation under the Recovery and Resilience Facility.
• The Commission registered €7.4 billion, equivalent to $8 billion, in pledges from donors worldwide during the Coronavirus Global Response pledging event.

The Commission’s successful placement will help sustain the momentum behind Europe’s recovery from the COVID-19 pandemic. The Commission published its third bi-annual report on the implementation and impact of SURE, the €100 billion instrument designed to protect jobs and incomes affected by the COVID-19 pandemic. The report confirmed that SURE has been successful in cushioning the impact of the pandemic and supporting the recovery in 2021. The Commission issued a further €9 billion in a dual tranche transaction under the NextGenerationEU recovery instrument. The deal is the 9th syndicated transaction under NextGenerationEU, and the 4th of 2022.

The European Commission announced over €3.3 billion of EU financial support mobilised jointly with the European Investment Bank to the benefit of the Western Balkans’ citizens. This package aims to address the immediate health and resulting humanitarian needs of the COVID-19 pandemic as well as help with the social and economic recovery. The Commission has reached a first agreement with the pharmaceutical company AstraZeneca to purchase a potential what is limefx forex broker vaccine against COVID-19 as well as to donate to lower and middle income countries or re-direct to other European countries. This agreement represents the basis for a contractual framework for the purchase of 300 million doses of the vaccine, with an option to purchase 100 million more, on behalf of EU Member States. Denmark, Greece, Hungary and Sweden have joined Germany and Romania as host states of the rescEU medical equipment reserve.

The main purpose of the Temporary Framework is to provide targeted support to otherwise viable companies that have entered into financial difficulty as a result of the coronavirus outbreak. The Commission has signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand name for Remdesivir. As from early August onwards, and in order to meet immediate needs, batches of Veklury will be made available to Member States and the UK, with the coordination and support of the Commission. The Council approved €87.4 billion of financial support to 16 member states in the form of EU loans under SURE – a temporary EU instrument to mitigate unemployment risks during the coronavirus crisis.

This financing will support the implementation of the crucial investment and reform measures outlined in Sweden’s recovery and resilience plan. It will play a crucial role in enabling Sweden to emerge stronger from the coronavirus pandemic. The Commission disbursed €450 million to Austria in a pre-financing payment under the Recovery and Resilience Facility.

iShares $ Short Duration Corp Bond UCITS

But the biotech space has never been more competitive, with new companies like Moderna making huge strides, and investors will watch that. They will also watch potential consolidation moves in the industry while being mindful that Pfizer has been involved in costly litigations in the past too. There are many aspects that need to be considered by anyone looking to go long or short in Pfizer stock.

The Commission disbursed €237 million to Latvia in pre-financing, equivalent to 13% of the country’s financial contribution as established in the Council Implementing Decision. The pre-financing payment will help to kick-start the implementation of the crucial investment and reform measures outlined in Latvia’s recovery and resilience plan. The Commission disbursed €231 million to Slovenia in pre-financing, equivalent to 13% of the country’s grant allocation under the Recovery and Resilience Facility.

The Commission welcomed the adoption of important new measures which will enable Member States to relieve EU hospitals, medical practitioners and individuals of Value-Added Tax when acquiring coronavirus vaccines and testing kits. The new rules should is forex.com a brokerage firm we can trust give better and cheaper access to the tools needed to prevent, detect and treat coronavirus. The Commission welcomed the political agreement reached between the European Parliament and the Council on the Recovery and Resilience Facility .

This action will help both EU and third-country companies to swiftly start production and place products on the internal market more easily while ensuring a high degree of safety. The Commission issued new practical advice to ensure that mobile workers within the EU, in particular those in critical occupations to fight the coronavirus pandemic, can reach their workplace. Together with the Guidance on the implementation of the temporary restriction on non-essential travel to the EU, this seeks to address practical concerns of citizens and companies affected by the measures taken to limit the spread of the coronavirus. The European Commission and the EU High Representative set out plans for a robust and targeted EU response to support partner countries’ efforts in tackling the coronavirus pandemic. The EU will secure financial support to partner countries amounting to more than €15.6 billion from existing external action resources.

La vacuna de Pfizer-BioNTech contra el COVID-19 ya está disponible para niños de 5 a 11 años

It called on Member States to take actions before autumn to ensure vigilance and continued coordination of health preparedness and response. The vaccine is effective and produced a similar immune response in children 5–11 as in older kids and adults ages 16–25. As with other routine vaccinations for children, the Pfizer-BioNTech COVID-19 vaccine underwent a thorough testing and review process by the FDA and an independent scientific committee to ensure it is safe and effective for children. On 8 December, UK grandmother Margaret Keenan became the first person in the world to receive the Pfizer Covid-19 jab. In the third quarter, Pfizer’s adjusted earnings soared 40% to $1.78 per share and were well above forecasts. The Covid vaccine, Comirnaty, and Paxlovid brought in a combined $11.92 billion in sales.

U.S. GDP rose slightly more than expected in the fourth quarter

This was a dual-tranche transaction, consisting of a €9 billion 5-year bond due on 6 July 2026 and a €6 billion 30-year bond due on 6 July 2051. The European Medicines Agency gave a positive opinion on two COVID-19 treatments – Ronapreve and Regkirona – identified by the Commission as promising therapeutics under the EU Strategy on COVID-19 Therapeutics. Both are treatments for use during the early stages of infection based on antiviral monoclonal antibodies. The Commission adopted its first annual report on the implementation of the Recovery and Resilience Facility , the centrepiece of NextGenerationEU.

Start Trading Stocks in 3 Days

The Commerce Department’s report comes even as inflation persists and the Federal Reserve continues to raise rates. The stock has gained 8.4% since the start of 2023, but recorded a more than 25% decline during the past 12 months. William Blair downgraded its rating for Viasat shares to market perform, citing the company’s declining number of customers and increasing pressure from competitors. GDP data released Thursday showed the economy expand at an annualized rate of 2.9% during the fourth quarter, the Commerce Department said.

The Commission concluded exploratory talks with the pharmaceutical company Novavax with a view to purchasing its potential vaccine against COVID-19. The envisaged contract with Novavax would provide for the possibility for all EU countries to purchase 100 million doses, and they could further purchase up to 100 million more doses. Traditionally, major pharmaceuticals like Pfizer were considered “safe haven” stocks; in other words, they were considered refuges for investors at times of uncertainty. Since the onset of the coronavirus pandemic this notion has changed because pharma companies are now so closely linked with the direct response to the virus itself. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price.

All four of these coronavirus vaccine stocks owned by the Gates Foundation could be winners over the long term. However, my view is that the best bets for investors among the group are Pfizer and BioNTech. The two companies are farther along in clinical testing with their coronavirus vaccine program than CureVac and Vir. The Gates Foundation first bought a position in BioNTech in September 2019, well before the COVID-19 pandemic hit. It invested $55 million in the biotech, with the potential for total funding to reach $100 million.

In addition, the Gates Foundation agreed to provide separate funding for several projects to develop vaccines based on CureVac’s messenger RNA platform. During the most recent surge, pediatric cases of COVID-19 rose by about 240% in the United States, demonstrating a need to protect children from the disease. Results from clinical trials that began in March 2021 showed the Pfizer-BioNTech COVID-19 vaccine was cost benefit analysis for beginners safe and effective to protect children ages 5–11 from COVID-19. It will be important to keep tabs on how Pfizer stock performs as Covid moves into its endemic phase and as the company expands its pipeline. Investors are closely watching the RSV vaccine, which could hit the market at the same time as a rival from GSK . By at least one measure, it was a sell when Pfizer stock dropped below its 50-day line.

As part of a Team Europe effort, the Commission has also announced a contribution of €400 million in guarantees to support COVAX and its objectives in the context of the Coronavirus Global Response. President of the European Commission Ursula von der Leyen welcomed COVID-19 scientific advisors from EU Member States to the first meeting of the EU scientific advice platform on COVID-19. The platform will facilitate more co-ordinated scientific advice on the approach to Member State COVID-19 public health measures across the EU. In its first NextGenerationEU transaction, the Commission raised a €20 billion via a ten-year bond due on 4 July 2031 to finance Europe’s recovery from the coronavirus crisis and its consequences. This is the largest-ever institutional bond issuance in Europe, the largest-ever institutional single tranche transaction and the largest amount the EU has raised in a single transaction. The EU Strategy on COVID-19 Therapeutics delivered its first outcome, with the announcement of the first portfolio of five therapeutics that could soon be available to treat patients across the EU.

Corinne Blanchard, vice president of lithium and clean tech equity research at Deutsche Bank, names one top stock pick. Markets have been buoyed by data this week showing improved business sentiment in Germany and an uptick in eurozone services and manufacturing activity, prompting optimism that a recession in the eurozone might be avoided. Slipped more than 2% premarket after the company posted a $220 million loss for the recent quarter as it grappled with the fallout from its year-end holiday debacle. With an overweight rating, saying investors are underestimating the lithium miner’s earnings growth outlook. Lithium is one of five critical minerals required in electrical vehicle batteries,according to the Congressional Research Service. Earnings per share for the recent quarter came in ahead of expectations, but the company said it expects net sales to be flat, or fall mid-single digits this year.